Horama is a clinical-stage biopharmaceutical company developing gene therapy therapies based on vectors derived from a recombinant adeno-associated virus (rAAV) targeting rare diseases of the retina.

Horama focuses on the development of gene therapy products to rare ophthalmology pathologies with recombinant adeno-associated viral vectors for orphan blinding diseases.

Horama was founded in 2014 & is based in Paris, France.


Horama has a diversified portfolio of its gene therapy platform, of which 2 main programs benefit from orphan drug designations: HORA PDE6B (retinitis pigmentosa), including the Phase I / II clinical trial, which began in November 2017, and HORA-RLPB1 (RPA or Retinitis Ponctuée Albescente) currently in the preclinical phase.


Horama is backed by leading investors such as Kurma Partners, Idinvest Partners, V-Bio Ventures, GO CAPITAL etc..



  • Year founded: 2014
  • Funding Info: €26.5M in 3 funding rounds (Last Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Paris
  • State: Ile-de-France
  • Country: France
Related businesses